Quanterix is disrupting diagnostics with a platform capable of measuring individual proteins in a variety of matrices including serum, plasma, cerebrospinal fluid, urine, and cell extracts. The platform’s single-molecule sensitivity makes it possible for users to accurately diagnose conditions, including heart attacks, long before symptoms appear, and to more accurately stratify patients for clinical trials.
Single protein measurement is the key. As Kevin Hrusovsky, executive chairman and CEO, points out, “Proteins capture information about how we live.” That includes environmental as well as genetic factors.
